Zealand Pharma A/S announced the appointment of Matthew Dallas as Vice President and Chief Financial Officer, effective October 7, 2019. As the chief financial officer, Mr. Dallas will report directly to Mr. Dulac and will lead the company's finance, legal, and investor relations departments. He will join the corporate management team to set overall business strategy.

Most recently, Mr. Dallas served as chief financial officer at Aveo Pharmaceuticals, and was additionally responsible for investor relations, facilities and information technology. He was previously CFO at CoLucid Pharmaceuticals, which was acquired by Eli Lilly. His earlier career included positions at Genzyme, NEN Life Science Products, and Kimberly Clark.

Mr. Dallas will be assisted in the transition by Ivan M. Møller, who has served as Zealand's interim CFO since April 2019. Mr. Møller will resume full focus on his continuing role as Senior Vice President of Technical Development & Operations.